Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Price, News & Analysis

Reata Pharmaceuticals logo

About Reata Pharmaceuticals Stock (NASDAQ:RETA)

Advanced Chart

Key Stats

Today's Range
$172.36
$172.36
50-Day Range
$168.70
$172.36
52-Week Range
$21.83
$172.46
Volume
N/A
Average Volume
1.09 million shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Headlines

RETA Stock Analysis - Frequently Asked Questions

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its earnings results on Monday, November, 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.32) by $0.35. Reata Pharmaceuticals's quarterly revenue was up 428.6% compared to the same quarter last year.

Reata Pharmaceuticals (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reata Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Netflix (NFLX), Approach Resources (AREX) and Intel (INTC).

Company Calendar

Last Earnings
11/08/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
321
Year Founded
2002

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-311,900,000.00
Pretax Margin
-373.40%

Debt

Sales & Book Value

Annual Sales
$23.48 million
Price / Cash Flow
N/A
Book Value
($1.79) per share
Price / Book
-96.29

Miscellaneous

Free Float
27,926,000
Market Cap
$6.58 billion
Optionable
Optionable
Beta
1.42

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:RETA) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners